Prognosis, Response
Conditions
Keywords
Multi-dimensional Signatures, NGS, Lung Cancer
Brief summary
This study aims to determine the clinical effectiveness of multi-dimensional signatures in predicting response and prognosis of lung cancer patients. The study is a multi-center perspective research of treatment planning for patients with lung cancer. To characterize clinical effectiveness, the progression-free survival (PFS) and overall survival (OS) impacts of multi-dimensional signatures will be estimated.
Detailed description
Multi-dimensional signatures, including NGS-based genotyping, and other essential detections such as immunohistochemistry (IHC), provides an opportunity to improve outcomes for patients by tailoring treatments to each individual's genomic profile. This is a multi-center single arm research study integrating multi-dimensional signatures into clinical decision-making for patients with lung cancer. The clinical effectiveness of multi-dimensional signatures is unknown in the real-world of clinics. To identify a counterfactual for Pred-lung approach, matching methods combined with administrative healthcare data will be used. The survival impacts of Pred-lung approach compared to usual care in matched controls will then be estimated.
Interventions
real world treatment by doctors
Sponsors
Study design
Eligibility
Inclusion criteria
* Patients with locally-advanced or metastasis lung cancer * Life expectancy \> 3 months
Exclusion criteria
* Age at diagnosis \<18 * refuse to enroll
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| PFS | through study completion, an average of 6 months | Progression-free survival |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| OS | through study completion, an average of 1 year | Overall survival |
Countries
China